GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
Global Blood Therapeutics, Inc. (GBT) announced its participation in a virtual fireside chat during the Guggenheim Genomic Medicines & Rare Disease Day on April 1, 2022, at 12:00 p.m. E.T. The chat will be accessible via live webcast on GBT's website, with a replay available for one month. GBT is focused on developing treatments for sickle cell disease (SCD), having introduced Oxbryta (voxelotor), the first FDA-approved medicine targeting the root cause of SCD. The company is also advancing its pipeline, including a Phase 3 program for inclacumab and GBT021601, aimed at improving SCD management.
- Participation in a notable industry event can enhance visibility.
- Advancements in pipeline programs, including inclacumab and GBT021601, indicate ongoing commitment to innovation in SCD treatment.
- None.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m. E.T.
The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
When is GBT's virtual fireside chat scheduled?
How can I access GBT's virtual fireside chat?
What is GBT's focus in the biopharmaceutical industry?
What is Oxbryta?
What are GBT's current pipeline programs?
